标题
Monoclonal antibodies for the prevention of migraine
作者
关键词
-
出版物
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 19, Issue 12, Pages 1307-1317
出版商
Informa UK Limited
发表日期
2019-09-25
DOI
10.1080/14712598.2019.1671350
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 Electronic Patient-Reported Outcome in Patients With Episodic and Chronic Migraine
- (2019) Rebecca M. Speck et al. HEADACHE
- CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review
- (2019) Ivan Urits et al. Current Pain and Headache Reports
- Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
- (2019) Peter J Goadsby et al. CEPHALALGIA
- Gepants for the treatment of migraine
- (2019) Andrea Negro et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class
- (2019) Richard Hargreaves et al. HEADACHE
- Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in chronic migraine
- (2019) Richard B. Lipton et al. NEUROLOGY
- Erenumab in chronic migraine with medication overuse
- (2019) Stewart J. Tepper et al. NEUROLOGY
- Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
- (2019) Bianca Raffaelli et al. JOURNAL OF HEADACHE AND PAIN
- Does inflammation have a role in migraine?
- (2019) Lars Edvinsson et al. Nature Reviews Neurology
- Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
- (2018) Messoud Ashina et al. CEPHALALGIA
- A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
- (2018) Orit Cohen-Barak et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Erenumab: First Global Approval
- (2018) Anthony Markham DRUGS
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
- (2018) Christophe Depre et al. HEADACHE
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CGRP as the target of new migraine therapies — successful translation from bench to clinic
- (2018) Lars Edvinsson et al. Nature Reviews Neurology
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention
- (2018) Vladimir Skljarevski et al. JAMA Neurology
- Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective
- (2018) Richard B. Lipton et al. JOURNAL OF MEDICAL ECONOMICS
- History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment
- (2018) Stewart J. Tepper HEADACHE
- A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
- (2018) Angelo Camporeale et al. BMC Neurology
- Galcanezumab: First Global Approval
- (2018) Yvette N. Lamb DRUGS
- Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018
- (2018) Stewart J. Tepper HEADACHE
- Early onset of efficacy with erenumab in patients with episodic and chronic migraine
- (2018) Todd Schwedt et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Human models of migraine — short-term pain for long-term gain
- (2017) Messoud Ashina et al. Nature Reviews Neurology
- Anti-CGRP antibodies block CGRP-induced diarrhea in mice
- (2017) Eric A. Kaiser et al. NEUROPEPTIDES
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects
- (2017) Thuy Vu et al. PHARMACEUTICAL RESEARCH
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
- (2017) David Monteith et al. Frontiers in Pharmacology
- Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2016) Theo Vos et al. LANCET
- Wiping Out CGRP: Potential Cardiovascular Risks
- (2016) Antoinette MaassenVanDenBrink et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- TEV-48125: a Review of a Monoclonal CGRP Antibody in Development for the Preventive Treatment of Migraine
- (2015) Sarah Walter et al. Current Pain and Headache Reports
- Monoclonal Antibodies for Migraine: Preventing Calcitonin Gene-Related Peptide Activity
- (2014) Marcelo E. Bigal et al. CNS DRUGS
- Pharmacological Trials in Migraine: It's Time to Reappraise Where the Headache Is and What the Pain Is Like
- (2014) Piero Barbanti et al. HEADACHE
- Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Calcitonin Gene-Related Peptide (CGRP) and Migraine Current Understanding and State of Development
- (2013) Marcelo E. Bigal et al. HEADACHE
- Validating Migraine-Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine
- (2011) Christine L. Bagley et al. HEADACHE
- OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine
- (2011) R. B. Lipton et al. NEUROLOGY
- CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat
- (2008) J Zeller et al. BRITISH JOURNAL OF PHARMACOLOGY
- Epidemiology and comorbidity of headache
- (2008) Rigmor Jensen et al. LANCET NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started